Association of 5-HT3B Receptor Gene Polymorphisms with the Efficacy of Ondansetron for Postoperative Nausea and Vomiting.
10.3349/ymj.2015.56.5.1415
- Author:
Min Soo KIM
1
;
Jeong Rim LEE
;
Eun Mi CHOI
;
Eun Ho KIM
;
Seung Ho CHOI
Author Information
1. Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea. csho99@yuhs.ac
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Postoperative nausea and vomiting;
5-HT3 receptor;
ondansetron;
genetic polymorphism
- MeSH:
Adult;
Aged;
Anesthesia, General;
Antiemetics/administration & dosage/*pharmacology;
Cholecystectomy, Laparoscopic;
Female;
Genome, Human;
Genotype;
Humans;
Incidence;
Injections, Intravenous;
Male;
Middle Aged;
Ondansetron/administration & dosage/*pharmacology;
Polymorphism, Genetic;
Postoperative Nausea and Vomiting/chemically induced/*drug therapy/epidemiology;
Receptors, Serotonin, 5-HT3/*drug effects/*genetics;
Time Factors
- From:Yonsei Medical Journal
2015;56(5):1415-1420
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Postoperative nausea and vomiting (PONV) is a common problem after general anesthesia. Although 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists have significantly reduced PONV, over 35% of patients treated with ondansetron can experience PONV. In this study, we investigated whether the Y129S and -100_-102AAG deletion polymorphisms of the 5-HT3B receptor gene affect the efficacy of ondansetron in preventing PONV. MATERIALS AND METHODS: Two hundred and forty-five adult patients who underwent laparoscopic cholecystectomy were enrolled. Ondansetron 0.1 mg/kg was intravenously administered 30 minutes before the end of surgery. Genomic DNA was prepared from blood samples using a nucleic acid isolation device. Both the Y129S variant and the -100_-102AAG deletion variant were screened for using a single base primer extension assay and a DNA direct sequencing method, respectively. The relationship between genetic polymorphisms and clinical outcomes of ondansetron treatment was investigated. RESULTS: Among the 5-HT3B AAG deletion genotypes, the incidence of PONV was higher in patients with the homomutant than with other genotypes during the first 2 hours after surgery (p=0.02). There were no significant differences in the incidence of PONV among genotypes at 2-24 hours after surgery. In the Y129S variants of the 5-HT3B receptor gene, there were no significant differences in the incidence of PONV among genotypes during the first 2 hours and at 2-24 hours after surgery. CONCLUSION: The response to ondansetron for PONV was significantly influenced by the -100_-102AAG deletion polymorphisms of the 5-HT3B gene. Thus, the -100_-102AAG deletion variants may be a pharmacogenetic predictor for responsiveness to ondansetron for PONV.
